Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: LOXO-101 | Statement: [Loxo Oncology, leadProductAlsoKnownAs, LOXO-101]

Target entity: LOXO-101
Context triple: [Loxo Oncology, leadProductAlsoKnownAs, LOXO-101]

• A. LOXO-305
  LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
• B. LOXO-195
  LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
• C. LOXO-292
  LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
• D. LOXO
  LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
• E. Imfinzi
  Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: LOXO-101
Triple: [Loxo Oncology, leadProductAlsoKnownAs, LOXO-101]

LOXO-101 is a targeted cancer therapy drug candidate developed by Loxo Oncology to inhibit TRK fusion proteins implicated in various tumors.

Target entity: LOXO-101
Target entity description: LOXO-101 is a targeted cancer therapy drug candidate developed by Loxo Oncology to inhibit TRK fusion proteins implicated in various tumors.

• A. LOXO-305
  LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
• B. LOXO-195 chosen
  LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
• C. LOXO-292
  LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
• D. LOXO
  LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
• E. Imfinzi
  Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
• F. None of above.

Target predicate: leadProductAlsoKnownAs
Context triple: [Loxo Oncology, leadProductAlsoKnownAs, LOXO-101]

• A. associatedCompanyMainProductLine
  Indicates that a company’s primary or main line of products is linked or related to a specified product category or product line.
• B. marketingNameOf
  Indicates that one entity is the marketing or brand name used to promote or refer to another entity.
• C. tradeNameIncludes
  Indicates that a trade name contains another name or term as part of its full designation.
• D. relatedBrand
  Indicates a relationship where one brand is associated with, connected to, or otherwise related to another brand.
• E. alsoKnownAs chosen
  Indicates that one entity is an alternative name, alias, or designation for another entity.
• F. None of above.